---
title: "Genscript flags 2025 loss on Legend impairment despite surge in licensing profit"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/278619983.md"
description: "Genscript Biotech (HK:1548) anticipates a significant rise in adjusted net profit for 2025, projecting between US$207.3 million and US$241.9 million, primarily due to increased licensing revenue. However, the company expects a full-year loss of US$505.8 million to US$585.6 million, largely due to non-cash charges related to its investment in Legend Biotech, including an impairment of US$378.2 million to US$437.9 million. Despite these challenges, Genscript remains confident in its long-term prospects, with a current analyst rating of Sell and a price target of HK$13.00."
datetime: "2026-03-10T14:37:45.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/278619983.md)
  - [en](https://longbridge.com/en/news/278619983.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/278619983.md)
---

# Genscript flags 2025 loss on Legend impairment despite surge in licensing profit

### Claim 70% Off TipRanks Premium

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

Genscript Biotech ( (HK:1548) ) just unveiled an update.

Genscript Biotech expects adjusted net profit from continuing operations for 2025 to surge to between US$207.3 million and US$241.9 million from US$59.8 million a year earlier, driven largely by a sharp rise in license revenue, notably sublicense income from LaNova Medicines. The company projects license revenue of US$256.1 million to US$298.8 million for the year, up from just US$2.4 million in 2024, underscoring strong momentum in its licensing business.

At the same time, heavy non-cash charges tied to its investment in Legend Biotech will push the group to a full-year loss of US$505.8 million to US$585.6 million, versus a prior-year profit inflated by a one-off unrealised gain from deconsolidating Legend. Genscript will book a substantial share of Legend’s losses and an impairment of US$378.2 million to US$437.9 million after a drop in Legend’s ADS price, though management highlights that Legend’s adjusted loss has narrowed significantly and reiterates confidence in its long-term prospects, with the group’s underlying profitability described as resilient once one-off and non-cash items are excluded.

The most recent analyst rating on (HK:1548) stock is a Sell with a HK$13.00 price target. To see the full list of analyst forecasts on Genscript Biotech stock, see the HK:1548 Stock Forecast page.

**More about Genscript Biotech**

Genscript Biotech Corporation is a Cayman Islands–incorporated biotech company listed in Hong Kong, operating in life sciences and cell therapy–related businesses. The group generates revenue from biotech products and services, including licensing income, and holds a significant associate stake in Nasdaq-listed Legend Biotech, reflecting a strategic focus on cell therapy innovation.

**Average Trading Volume:** 8,618,525

**Technical Sentiment Signal:** Sell

**Current Market Cap:** HK$25.41B

### Related Stocks

- [01548.HK](https://longbridge.com/en/quote/01548.HK.md)
- [LEGN.US](https://longbridge.com/en/quote/LEGN.US.md)

## Related News & Research

- [Genscript Biotech Sets 2026 AGM to Approve Accounts, Board Mandates and Share Issuance Authority](https://longbridge.com/en/news/282529201.md)
- [Jefferies Reaffirms Their Buy Rating on Genscript Biotech (GNNSF)](https://longbridge.com/en/news/281717215.md)
- [ANALYSIS-PepsiCo faces pressure to show Elliott-triggered turnaround is working](https://longbridge.com/en/news/282689843.md)
- [Contemporary Amperex Technology Co., Limited Class H (3750) Gets a Buy from CLSA](https://longbridge.com/en/news/282610766.md)
- [BUZZ-Genscript Biotech climbs as cancer drug CARVYKTI generated $597 mln sales](https://longbridge.com/en/news/282790609.md)